Volume 3, Issue 3, Pages (March 2006)

Slides:



Advertisements
Similar presentations
Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.
Advertisements

Chun-Ching Shih, Cheng-Hsiu Lin, Wei-Li Lin 
Volume 5, Issue 10, Pages (October 2016)
Peter L. Lee, Yuefeng Tang, Huawei Li, David A. Guertin 
Differential effects of angiopoietin-like 4 in brain and muscle on regulation of lipoprotein lipase activity  Sara Gry Vienberg, André Kleinridders, Ryo.
Volume 10, Issue 4, Pages (October 2009)
Volume 24, Issue 3, Pages (September 2016)
Volume 13, Issue 6, Pages (June 2011)
Volume 24, Issue 6, Pages (December 2016)
Volume 24, Issue 3, Pages (September 2016)
Grzegorz Sumara, Olga Sumara, Jason K. Kim, Gerard Karsenty 
Volume 23, Issue 3, Pages (March 2016)
Volume 6, Issue 3, Pages (September 2007)
Volume 22, Issue 3, Pages (March 2015)
Volume 12, Issue 4, Pages (October 2010)
Volume 14, Issue 4, Pages (October 2011)
Volume 11, Issue 1, Pages (January 2010)
Volume 14, Issue 3, Pages (September 2011)
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Volume 4, Issue 3, Pages (September 2006)
Volume 17, Issue 5, Pages (May 2013)
Volume 14, Issue 6, Pages (December 2011)
Volume 51, Issue 6, Pages (September 2006)
Volume 3, Issue 3, Pages (March 2006)
Volume 20, Issue 1, Pages (July 2014)
Volume 46, Issue 2, Pages (April 2012)
Volume 19, Issue 1, Pages (January 2014)
Volume 18, Issue 5, Pages (November 2013)
Volume 11, Issue 4, Pages (April 2010)
Volume 22, Issue 6, Pages (February 2018)
Volume 22, Issue 1, Pages (January 2018)
Volume 16, Issue 7, Pages (August 2016)
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Diet-Induced Obese Mice Retain Endogenous Leptin Action
Critical Role for Hypothalamic mTOR Activity in Energy Balance
Volume 1, Issue 1, Pages (January 2005)
Volume 9, Issue 2, Pages (February 2009)
Volume 20, Issue 1, Pages (July 2014)
Volume 21, Issue 5, Pages (May 2015)
Volume 17, Issue 4, Pages (April 2013)
Volume 10, Issue 5, Pages (November 2009)
Volume 10, Issue 1, Pages (July 2009)
Volume 25, Issue 4, Pages e4 (April 2017)
Volume 9, Issue 1, Pages (January 2009)
Volume 5, Issue 5, Pages (May 2007)
Volume 22, Issue 2, Pages (August 2015)
Volume 3, Issue 6, Pages (June 2006)
Volume 15, Issue 5, Pages (May 2012)
Volume 27, Issue 2, Pages e4 (February 2018)
Volume 6, Issue 3, Pages (September 2007)
Volume 6, Issue 5, Pages (November 2007)
Knockdown of NPY Expression in the Dorsomedial Hypothalamus Promotes Development of Brown Adipocytes and Prevents Diet-Induced Obesity  Pei-Ting Chao,
Induction of Leptin Resistance by Activation of cAMP-Epac Signaling
Identification of SH2-B as a key regulator of leptin sensitivity, energy balance, and body weight in mice  Decheng Ren, Minghua Li, Chaojun Duan, Liangyou.
Volume 7, Issue 3, Pages (March 2008)
Volume 22, Issue 2, Pages (August 2015)
Volume 9, Issue 6, Pages (June 2009)
Volume 20, Issue 4, Pages (October 2014)
Volume 4, Issue 5, Pages (November 2006)
Volume 1, Issue 6, Pages (June 2005)
Hepatic fuel metabolism in male 5αR1-KO and WT mice
Clémence Blouet, Hiraku Ono, Gary J. Schwartz  Cell Metabolism 
Unlikely partners in weight loss?
Adipose Fatty Acid Oxidation Is Required for Thermogenesis and Potentiates Oxidative Stress-Induced Inflammation  Jieun Lee, Jessica M. Ellis, Michael J.
Volume 24, Issue 6, Pages (December 2016)
Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice  Jun Yoshino, Kathryn F. Mills,
Volume 5, Issue 3, Pages (March 2007)
Brown Adipose Tissue Thermogenic Capacity Is Regulated by Elovl6
Volume 16, Issue 3, Pages (September 2012)
Volume 4, Issue 4, Pages (October 2006)
Presentation transcript:

Volume 3, Issue 3, Pages 167-175 (March 2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents  Hilary A. Overton, Adam J. Babbs, Sheila M. Doel, Matthew C.T. Fyfe, Lisa S. Gardner, Graeme Griffin, Helen C. Jackson, Martin J. Procter, Chrystelle M. Rasamison, Mads Tang-Christensen, Peter S. Widdowson, Geoffery M. Williams, Christine Reynet  Cell Metabolism  Volume 3, Issue 3, Pages 167-175 (March 2006) DOI: 10.1016/j.cmet.2006.02.004 Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 1 Structures of OEA, PSN375963, and PSN632408 Cell Metabolism 2006 3, 167-175DOI: (10.1016/j.cmet.2006.02.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 2 Fatty-acid ethanolamides are agonists at GPR119 Fold induction of signal (means; n = 4) by fatty-acid ethanolamides in yeast fluorimetric assay for (A) human GPR119 and (B) mouse GPR119. OEA—filled triangles; PEA—open triangles; SEA—filled squares; AEA—open diamonds (see text for definitions). Cell Metabolism 2006 3, 167-175DOI: (10.1016/j.cmet.2006.02.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 3 GPR119 agonists stimulate adenylate cyclase in mammalian cells A) Quantitative RT-PCR analysis of hGPR119-specific mRNA levels in HEK-OSGPR116 cells treated with increasing concentrations of tetracycline. B) Responses of intracellular cAMP levels to treatment of tetracycline-induced HEK-OSGPR116 cells with OEA (filled circles) or PSN632408 (open squares). Results expressed as means ± SEM. Cell Metabolism 2006 3, 167-175DOI: (10.1016/j.cmet.2006.02.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 4 Acute dosing of rats with GPR119 agonists A) Cumulative food intake (g/kg body weight) in weight-matched groups of 8 or 9 male Sprague-Dawley rats (weight range 352–425 g) after i.p. administration of vehicle, OEA (30 mg/kg), and PSN632408 (100 mg/kg). Results are expressed as means + SEM. Significant differences from the vehicle-treated controls are denoted by ∗∗p < 0.01 (one-way ANOVA followed by Dunnett's multiple comparison test). B) Cumulative food intake (g/kg body weight) and (C) locomotor activity (cumulative consecutive beam breaks) in weight-matched groups of 10 or 11 male Sprague-Dawley rats (weight range 293–339 g) after i.p. administration of vehicle (open squares) or PSN632408 at 10 mg/kg (filled triangles) or 30 mg/kg (filled diamonds). Data are expressed as means + SEM. Significant differences from the vehicle-treated controls are denoted by ∗p < 0.05 (ANOVA followed by Fisher's post-hoc test). Cell Metabolism 2006 3, 167-175DOI: (10.1016/j.cmet.2006.02.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 5 Subchronic dosing of DIO rats with PSN632408 A) Cumulative food intake (g/kg body weight) and (B) body weight (percentage of day 0 value) for groups of 9 or 10 rats dosed daily p.o. (commencing on day 0) with vehicle (open squares; mean body weight 545 ± 17 g on day 0) or with 100 mg/kg PSN632408 (filled circles; mean body weight 551 ± 14 g on day 0). Results are presented as means + SEM. Significant differences from the vehicle-treated controls are denoted by ∗p < 0.05 (ANOVA followed by Fisher's post-hoc test). C) Weights of fat pad masses removed at day 14 (24 hr after last dose) from rats treated with vehicle (open bars) or PSN632408 (shaded bars). ING = inguinal, EP = epididymal, MES = mesenteric, RP = retroperitoneal, IBAT = intrascapular brown adipose tissue. Values expressed in g (mean + SEM). Significant differences from the vehicle-treated controls are denoted by ∗p < 0.05 (ANOVA factorial, Fisher's post-hoc test). Cell Metabolism 2006 3, 167-175DOI: (10.1016/j.cmet.2006.02.004) Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 6 Subchronic dosing of normal rats on high-fat diet with PSN632408 and sibutramine A) Cumulative food intake (kJ/kg body weight) and (B) body weight (percentage of day 0 value) for groups of 10 rats dosed daily p.o. (commencing on day 0) with vehicle (open squares; mean body weight 305 ± 7 g on day 0), 100 mg/kg PSN632408 (filled circles; mean body weight 306 ± 5 g on day 0), or 5 mg/kg sibutramine hydrochloride hydrate (filled triangles; mean body weight 303 ± 5 g on day 0). A further group of 4 rats on standard chow diet was dosed daily with vehicle (open circles; mean body weight 275 ± 5 g on day 0). Results are presented as means + SEM. Significant differences from the vehicle-treated HFD controls (p < 0.05; ANOVA followed by Fisher's post-hoc test) are denoted by ∗ (PSN632408), + (sibutramine), and # (chow-fed controls). C) Weights of fat pad masses removed on day 24 (24 hr after final dose) from rats treated with vehicle, PSN632408, sibutramine, or chow-fed controls, respectively. ING = inguinal, EP = epididymal, MES = mesenteric, RP = retroperitoneal, WAT = total of ING, EP, MES, and RP. Values expressed in g (mean + SEM). Significant differences from the vehicle-treated HFD controls are denoted by ∗ (p < 0.05; ANOVA factorial, Fisher's post-hoc test). D) Plasma leptin levels at day 24 (24 hr after final dose) from rats treated with vehicle, PSN632408, sibutramine, or chow-fed controls. Values expressed in ng/ml (mean + SEM). Significant differences from the vehicle-treated HFD controls are denoted by ∗ (p < 0.05; ANOVA, Bonferroni's modified T-test). Cell Metabolism 2006 3, 167-175DOI: (10.1016/j.cmet.2006.02.004) Copyright © 2006 Elsevier Inc. Terms and Conditions